Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CC-90001 for idiopathic pulmonary fibrosis was terminated; no results indicate efficacy or safety outcomes were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosis
• Idiopathic Interstitial Pneumonias
• Idiopathic Pulmonary Fibrosis
• Lung Diseases
• Lung Diseases Interstitial
• Respiratory Tract Diseases

Drugs mentioned

• CC-90001

Snippet

Sponsor: Celgene | Conditions: Idiopathic Pulmonary Fibrosis, Fibrosis | Phase 2 | Status: TERMINATED | Results posted: 2023-06-28